PubRank

William MacNee

Author PubWeight™ 138.73‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005 7.20
2 Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011 5.69
3 Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010 5.17
4 Diesel exhaust inhalation causes vascular dysfunction and impaired endogenous fibrinolysis. Circulation 2005 4.71
5 Living and dying with severe chronic obstructive pulmonary disease: multi-perspective longitudinal qualitative study. BMJ 2011 3.61
6 Six-minute-walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization. Am J Respir Crit Care Med 2012 3.44
7 Combustion-derived nanoparticles: a review of their toxicology following inhalation exposure. Part Fibre Toxicol 2005 3.12
8 Adverse cardiovascular effects of air pollution. Nat Clin Pract Cardiovasc Med 2008 3.00
9 Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One 2012 2.52
10 Effectiveness of telemonitoring integrated into existing clinical services on hospital admission for exacerbation of chronic obstructive pulmonary disease: researcher blind, multicentre, randomised controlled trial. BMJ 2013 2.40
11 4-Hydroxy-2-nonenal, a specific lipid peroxidation product, is elevated in lungs of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002 2.38
12 Expression of adhesion molecules during apoptosis of circulating neutrophils in COPD. Chest 2004 2.33
13 The COPD control panel: towards personalised medicine in COPD. Thorax 2012 2.32
14 The pro-inflammatory effects of low-toxicity low-solubility particles, nanoparticles and fine particles, on epithelial cells in vitro: the role of surface area. Occup Environ Med 2007 2.29
15 Oxidative stress and calcium signaling in the adverse effects of environmental particles (PM10). Free Radic Biol Med 2003 2.28
16 A combined pulmonary-radiology workshop for visual evaluation of COPD: study design, chest CT findings and concordance with quantitative evaluation. COPD 2012 2.07
17 The pulmonary toxicology of ultrafine particles. J Aerosol Med 2002 2.02
18 Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration 2010 2.00
19 The effect of smoking on the transcriptional regulation of lung inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006 1.99
20 Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012 1.99
21 A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. Hum Mol Genet 2011 1.98
22 Piloting tele-monitoring in COPD: a mixed methods exploration of issues in design and implementation. Prim Care Respir J 2012 1.92
23 Systemic soluble receptor for advanced glycation endproducts is a biomarker of emphysema and associated with AGER genetic variants in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013 1.79
24 Oxidative stress and TNF-alpha induce histone acetylation and NF-kappaB/AP-1 activation in alveolar epithelial cells: potential mechanism in gene transcription in lung inflammation. Mol Cell Biochem 2002 1.77
25 Genome-wide association analysis of blood biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012 1.72
26 Identification of five chronic obstructive pulmonary disease subgroups with different prognoses in the ECLIPSE cohort using cluster analysis. Ann Am Thorac Soc 2015 1.72
27 An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015 1.63
28 Socioeconomic deprivation increases the effect of winter on admissions to hospital with COPD: retrospective analysis of 10 years of national hospitalisation data. Prim Care Respir J 2013 1.60
29 Metal oxide nanoparticles induce unique inflammatory footprints in the lung: important implications for nanoparticle testing. Environ Health Perspect 2010 1.57
30 Cryptic haplotypes of SERPINA1 confer susceptibility to chronic obstructive pulmonary disease. Hum Mutat 2006 1.53
31 Soluble transition metals cause the pro-inflammatory effects of welding fumes in vitro. Toxicol Appl Pharmacol 2004 1.47
32 Graphene-based nanoplatelets: a new risk to the respiratory system as a consequence of their unusual aerodynamic properties. ACS Nano 2012 1.46
33 Exposure to concentrated ambient particles does not affect vascular function in patients with coronary heart disease. Environ Health Perspect 2008 1.45
34 Pulmonary function is associated with distal aortic calcium, not proximal aortic distensibility. MESA lung study. COPD 2011 1.41
35 Histone acetylation regulates epithelial IL-8 release mediated by oxidative stress from environmental particles. Am J Physiol Lung Cell Mol Physiol 2002 1.41
36 Pulmonary and systemic effects of short-term inhalation exposure to ultrafine carbon black particles. Toxicol Appl Pharmacol 2004 1.36
37 Cigarette smoke prevents apoptosis through inhibition of caspase activation and induces necrosis. Am J Respir Cell Mol Biol 2003 1.35
38 Lung function in idiopathic pulmonary fibrosis--extended analyses of the IFIGENIA trial. Respir Res 2009 1.34
39 Airway dimensions in COPD: relationships with clinical variables. Respir Med 2010 1.30
40 Predicting outcomes from 6-minute walk distance in chronic obstructive pulmonary disease. J Am Med Dir Assoc 2011 1.28
41 Increased platelet activation in patients with stable and acute exacerbation of COPD. Thorax 2011 1.25
42 Cigarette smoke disrupts VEGF165-VEGFR-2 receptor signaling complex in rat lungs and patients with COPD: morphological impact of VEGFR-2 inhibition. Am J Physiol Lung Cell Mol Physiol 2005 1.22
43 Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team. Am J Respir Crit Care Med 2014 1.20
44 Potential role of IL-8, platelet-activating factor and TNF-alpha in the sequestration of neutrophils in the lung: effects on neutrophil deformability, adhesion receptor expression, and chemotaxis. Eur J Immunol 2002 1.20
45 Role of inflammation in cardiopulmonary health effects of PM. Toxicol Appl Pharmacol 2005 1.12
46 Antioxidant pharmacological therapies for COPD. Curr Opin Pharmacol 2012 1.10
47 Association of MMP-2 polymorphisms with severe and very severe COPD: a case control study of MMPs-1, 9 and 12 in a European population. BMC Med Genet 2010 1.08
48 Living and dying with severe chronic obstructive pulmonary disease: multi-perspective longitudinal qualitative study. BMJ Support Palliat Care 2011 1.08
49 Authors response. The chronic obstructive pulmonary disease (COPD) control panel: towards personalised medicine in COPD. Thorax 2013 1.07
50 The impact of a telemetric chronic obstructive pulmonary disease monitoring service: randomised controlled trial with economic evaluation and nested qualitative study. Prim Care Respir J 2009 1.07
51 Metabolic profiling detects biomarkers of protein degradation in COPD patients. Eur Respir J 2011 1.06
52 Targeted metabolomics identifies perturbations in amino acid metabolism that sub-classify patients with COPD. Mol Biosyst 2012 1.02
53 Molecular mechanism of transforming growth factor (TGF)-beta1-induced glutathione depletion in alveolar epithelial cells. Involvement of AP-1/ARE and Fra-1. J Biol Chem 2002 1.02
54 Airways inflammation and treatment during acute exacerbations of COPD. Int J Chron Obstruct Pulmon Dis 2008 1.00
55 The SERPINE2 gene and chronic obstructive pulmonary disease. Am J Hum Genet 2006 0.99
56 Regulation of LPS-mediated inflammation in vivo and in vitro by the thiol antioxidant Nacystelyn. Am J Physiol Lung Cell Mol Physiol 2004 0.97
57 Ultrafine carbon black particles inhibit human lung fibroblast-mediated collagen gel contraction. Am J Respir Cell Mol Biol 2003 0.97
58 Predictive value of in vitro assays depends on the mechanism of toxicity of metal oxide nanoparticles. Part Fibre Toxicol 2013 0.96
59 Opportunities and challenges in the genetics of COPD 2010: an International COPD Genetics Conference report. COPD 2011 0.93
60 The role of IREB2 and transforming growth factor beta-1 genetic variants in COPD: a replication case-control study. BMC Med Genet 2011 0.93
61 Inflammatory lung secretions inhibit dendritic cell maturation and function via neutrophil elastase. Am J Respir Crit Care Med 2006 0.92
62 CT-measured bone attenuation in patients with chronic obstructive pulmonary disease: relation to clinical features and outcomes. J Bone Miner Res 2013 0.91
63 Update in chronic obstructive pulmonary disease 2008. Am J Respir Crit Care Med 2009 0.90
64 Guidelines for chronic obstructive pulmonary disease. BMJ 2004 0.90
65 Aging, inflammation, and emphysema. Am J Respir Crit Care Med 2011 0.90
66 Nacystelyn inhibits oxidant-mediated interleukin-8 expression and NF-kappaB nuclear binding in alveolar epithelial cells. Free Radic Biol Med 2002 0.87
67 Glutathione prevents inhibition of fibroblast-mediated collagen gel contraction by cigarette smoke. Am J Physiol Lung Cell Mol Physiol 2002 0.86
68 Chronic obstructive pulmonary disease and cardiovascular diseases: a "vulnerable" relationship. Am J Respir Crit Care Med 2013 0.86
69 Surface functionalization affects the zeta potential, coronal stability and membranolytic activity of polymeric nanoparticles. Nanotoxicology 2013 0.86
70 Neuromuscular electrical stimulation prevents muscle function deterioration in exacerbated COPD: a pilot study. Respir Med 2012 0.85
71 Neurological and endocrinological disorders: orphans in chronic obstructive pulmonary disease. Respir Med 2011 0.83
72 Permeability, inflammation and oxidant status in airspace epithelium exposed to ozone. Respir Med 2006 0.83
73 The European Respiratory Society spirometry tent: a unique form of screening for airway obstruction. Eur Respir J 2012 0.82
74 Chronic obstructive pulmonary disease and its comorbidities. Br J Hosp Med (Lond) 2011 0.81
75 The search for distinct and clinically useful phenotypes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013 0.80
76 [Pathogenesis of chronic obstructive pulmonary disease. Cellular mechanisms (part I)]. Wiad Lek 2006 0.78
77 Common genetic variants associated with resting oxygenation in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2014 0.78
78 Chronic cough and sputum production are associated with worse clinical outcomes in stable asthma. Respir Med 2013 0.78
79 [Pathogenesis of chronic obstructive pulmonary disease. Molecular mechanisms (part II)]. Wiad Lek 2006 0.77
80 Haplotypes of the alpha-1 antitrypsin gene in healthy controls and Z deficiency patients. Hum Mutat 2004 0.77
81 Associations between COPD related manifestations: a cross-sectional study. Respir Res 2013 0.77
82 Lack of systemic oxidative stress during PAF challenge in mild asthma. Respir Med 2004 0.77
83 Human models of exacerbations of COPD: no extrapolation needed. Am J Respir Crit Care Med 2011 0.77
84 Evaluating the role of inflammation in chronic airways disease: the ERICA study. COPD 2014 0.77
85 Clinic practice guidelines: more of the same? Am J Respir Crit Care Med 2011 0.77
86 Forced expiratory volume in one second predicts length of stay and in-hospital mortality in patients undergoing cardiac surgery: a retrospective cohort study. PLoS One 2013 0.75
87 Response. Chest 2013 0.75
88 Should we treat chronic obstructive pulmonary disease as a cardiovascular disease? Expert Rev Respir Med 2015 0.75